Increased expression of PYCR1 has since been confirmed in different cancers, including melanoma, NSCLC, renal cell carcinoma, breast cancer, colorectal cancer, prostate cancer, hepatocellular carcinoma, and isocitrate dehydrogenase 1 (IDH1)-mutant gliomas41,42,64,96–102. This evidence concerns the gene PYCR1 and prostate carcinoma.